Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yueju Pill in Advanced Biliary Tract Cancer
NCT07169916Not yet recruiting
- Sponsor
- Fudan University
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Randomised, double-blind trial in biliary tract cancer (BTC), anxiety disorder and major depressive disorder (MDD) comparing Yueju Group with Placebo Group (2 arms). Primary endpoint: Improvement in quality of life at 18 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
Yueju Pill
03
Conditions
biliary tract cancer (BTC)anxiety disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07169916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169916.